

2019 Current Fiscal Year Report: National Cancer Institute Board of Scientific Advisors

Report Run Date: 02/19/2020 01:33:03 AM

1. Department or Agency Department of Health and Human Services	2. Fiscal Year 2019
3. Committee or Subcommittee National Cancer Institute Board of Scientific Advisors	3b. GSA Committee No. 1483

4. Is this New During Fiscal Year? No	5. Current Charter 10/08/2019	6. Expected Renewal Date	7. Expected Term Date
---	---	---------------------------------	------------------------------

8a. Was Terminated During Fiscal Year? No	8b. Specific Termination Authority	8c. Actual Term Date
---	---	-----------------------------

9. Agency Recommendation for Next Fiscal Year Continue	10a. Legislation Req to Terminate? Not Applicable	10b. Legislation Pending? Not Applicable
--	---	--

11. Establishment Authority Authorized by Law

12. Specific Establishment Authority 42 U.S.C. 285a-2(b)(7)	13. Effective Date 11/20/1985	14. Committee Type Continuing	14c. Presidential? No
---	---	---	---------------------------------

15. Description of Committee Scientific Technical Program Advisory Board

16a. Total Number of Reports 1

16b. Report Date 05/28/2019	Report Title NCI Board of Scientific Advisors ad hoc Working Group on Immunology of Therapies & Vaccines and Research Structure Final Working Group Report
---------------------------------------	--

Number of Committee Reports Listed: 1

17a. Open 3 **17b. Closed** 0 **17c. Partially Closed** 0 **Other Activities** 0 **17d. Total** 3

Meetings and Dates

Purpose	Start	End
Program Advisory and/or Policy	12/04/2018	- 12/04/2018
Program Advisory and/or Policy	03/25/2019	- 03/25/2019
Program Advisory and/or Policy	06/10/2019	- 06/10/2019

Number of Committee Meetings Listed: 3

	Current FY	Next FY
18a(1). Personnel Pmts to Non-Federal Members	\$11,200.00	\$11,200.00
18a(2). Personnel Pmts to Federal Members	\$0.00	\$0.00
18a(3). Personnel Pmts to Federal Staff	\$64,766.00	\$61,432.00
18a(4). Personnel Pmts to Non-Member Consultants	\$0.00	\$0.00
18b(1). Travel and Per Diem to Non-Federal Members	\$38,113.00	\$38,362.00

18b(2). Travel and Per Diem to Federal Members	\$0.00	\$0.00
18b(3). Travel and Per Diem to Federal Staff	\$0.00	\$0.00
18b(4). Travel and Per Diem to Non-member Consultants	\$0.00	\$0.00
18c. Other(rents,user charges, graphics, printing, mail, etc.)	\$94,652.00	\$95,599.00
18d. Total	\$208,731.00	\$206,593.00
19. Federal Staff Support Years (FTE)	0.40	0.30

20a. How does the Committee accomplish its purpose?

The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute's programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In 2019, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. BSA members provided insights regarding a final report from the BSA ad hoc Working Group on Immunology of Therapies & Vaccines and Research Structure. As a result, they approved several recommendations centered on three main areas - understanding KSHV, obtaining cancer biospecimens from individuals infected with HIV, and promoting individual investigator-initiated research within the HIV malignancy field. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Cellular Cancer Biology Imaging Research Resource Program (New RFA); Molecular and Biological Effects of High Linear Energy Transfer Radiation Exposure (New RFA); Informatics Technology for Cancer Research (New RFA/Cooperative Agreement [Coop. Agr.]); Optimizing Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care (New RFA); Research on Pediatric, Adolescent, and Young Adult Survivorship Through the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act (New RFA); Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events (New RFA); Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq) (New RFA/Coop. Agr.); Cancer Intervention and Surveillance Modeling Network (CISNET) (Reissue RFA/Coop. Agr.); AIDS Malignancy Consortium (AMC) (Reissue RFA/Coop. Agr./Limited Competition); Next Gen Technology for Next Gen Cancer Models (New RFA/Coop. Agr.); Mechanisms of Cancer Drug Resistance Competing Revisions (New RFA); Pediatric Brain Tumor Consortium (Reissue RFA/Coop. Agr./Limited Competition); Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Consortium (Reissue RFA/Coop. Agr.); U.S. and Low- and Middle-Income Country (LMIC) HIV Malignancy Research

Networks (RFA/Coop. Agr.); and Biospecimen Banks to Support NCI National Clinical Trials Network (NCTN), NCI Community Oncology Research Program (NCORP), and CTEP-Supported Early Trials/Studies (Reissue RFA/Coop. Agr./Limited Competition).

20b. How does the Committee balance its membership?

The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.

20c. How frequent and relevant are the Committee Meetings?

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2018 and June 2019 meetings. The Board also met in March 2019. The Board's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program, as well as concept review of grant and contract initiatives in the extramural research program. According to the Board's charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of Request for Applications (RFAs); cooperative agreements; and research and development contracts. The BSA ad hoc Subcommittee on HIV/AIDS Malignancy met on 24 May 2019. The BSA ad hoc Working Group on Immunology of Therapies and Vaccines and Research Structure met on 8 November 2018. The BSA ad

hoc Working Group on Prevention met on 11 September and 19 September 2019.

20d. Why can't the advice or information this committee provides be obtained elsewhere?

This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.

20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

21. Remarks

Members: The terms for Kenneth Anderson and Dafna Bar-Sagi have changed due to reappointments. The terms for Graham Colditz, Diane Quale, Eileen White, and Kevin White have changed due to administrative extensions. As such, their term of service end dates are different than what was reported on the FY18 ACR. Costs: The decrease in Federal Staff costs in FY19 was due to incorrectly reported salaries in the FY18 ACR. The increase in operating costs for FY19 was due to all BSA meetings being held in person and an increase in working group meetings. The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.

Designated Federal Officer

PAULETTE S. GRAY DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI

Committee Members	Start	End	Occupation	Member Designation
ANDERSON, KENNETH	12/18/2013	06/30/2021	KRAFT FAMILY PROFESSOR OF MEDICINE, HARVARD MEDICAL SCHOOL & DANA FARBER CANCER INSTITUTE	Special Government Employee (SGE) Member
BAR-SAGI, DAFNA	10/29/2013	06/30/2021	VICE DEAN FOR SCIENCE, SENIOR VICE PRESIDENT, AND CHIEF SCIENTIFIC OFFICER, NEW YORK UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
BECICH, MICHAEL	11/27/2016	06/30/2021	PROFESSOR, PATHOLOGY INFORMATION SCIENCES/TELECOMMUNICATIONS, CLINICAL/TRANSLATIONAL SCIENCES, UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
BECKERLE, MARY	02/19/2019	06/30/2022	DISTINGUISHED PROFESSOR OF BIOLOGY AND CEO & DIRECTOR, HUNTSMAN CANCER INSTITUTE, UNIVERSITY OF UTAH	Special Government Employee (SGE) Member

BONDY, MELISSA	11/26/2017	06/30/2021	PROFESSOR AND ASSOCIATE DIRECTOR, DEPARTMENT OF MEDICINE, BAYLOR COLLEGE OF MEDICINE	Special Government Employee (SGE) Member
BRAWLEY, OTIS	04/29/2019	06/30/2023	BLOOMBERG DISTINGUISHED PROFESSOR OF ONCOLOGY AND EPIDEMIOLOGY, SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER, JOHNS HOPKINS UNIVERSITY	Special Government Employee (SGE) Member
COLDITZ, GRAHAM	01/27/2013	12/31/2019	NISS-GAIN PROFESSOR OF SURGERY, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
COUNTER, CHRISTOPHER	02/05/2017	06/30/2021	PROFESSOR OF PHARMACOLOGY AND CANCER BIOLOGY, DUKE UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
FERRANS, CAROL	03/06/2016	06/30/2020	ASSOCIATE DEAN FOR RESEARCH, COLLEGE OF NURSING, UNIVERSITY OF ILLINOIS CHICAGO	Special Government Employee (SGE) Member
FLAHERTY, KEITH	03/31/2019	06/30/2023	DIRECTOR OF CLINICAL RESEARCH, MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER	Special Government Employee (SGE) Member
KNUDSEN, KAREN	02/03/2019	06/30/2023	HILARY KOPROWSKI ENDOWED PROFESSOR AND DIRECTOR, SIDNEY KIMMEL CANCER CENTER, THOMAS JEFFERSON UNIVERSITY	Special Government Employee (SGE) Member
LACEY, JAMES	03/06/2016	06/30/2020	DIRECTOR AND PROFESSOR, DIVISION OF HEALTH ANALYTICS, BECKMAN RESEARCH INSTITUTE, CITY OF HOPE	Special Government Employee (SGE) Member
LE BEAU, MICHELLE	02/03/2019	06/30/2023	ARTHUR AND MARIAN EDELSTEIN PROFESSOR OF MEDICINE AND DIRECTOR, UNIVERSITY OF CHICAGO COMPREHENSIVE CANCER CENTER, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
PLEVRITIS, SYLVIA	02/05/2017	06/30/2021	PROFESSOR, DEPARTMENT OF RADIOLOGY AND BIOMEDICAL DATA SCIENCE, STANFORD UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
QUALE, DIANE	09/05/2014	09/30/2019	CO-FOUNDER AND PRESIDENT, BLADDER CANCER ADVOCACY NETWORK	Special Government Employee (SGE) Member
RATHMELL, W.	03/17/2019	06/30/2023	CORNELIUS A. CRAIG PROFESSOR AND DIRECTOR, DIVISION OF HEMATOLOGY AND ONCOLOGY, VANDERBILT UNIVERSITY MEDICAL CENTER	Special Government Employee (SGE) Member
ROBISON, LESLIE	03/31/2019	06/30/2022	CHAIRMAN, DEPARTMENT OF EPIDEMIOLOGY AND CANCER CONTROL, AND ASSOCIATE DIRECTOR, ST. JUDE COMPREHENSIVE CANCER CENTER	Special Government Employee (SGE) Member
ROUSSEL (SHERR), MARTINE	02/25/2013	06/30/2020	ST. JUDE CHILDREN'S RESEARCH'S ENDOWED CHAIR IN MOLECULAR ONCOGENESIS AND FULL PROFESSOR, ST. JUDE CHILDREN'S RESEARCH HOSP AND UNIVERSITY OF TENNESSEE	Special Government Employee (SGE) Member

SCHREIBER, ROBERT	11/26/2017	06/30/2021	ANDREW M. AND JANE M. BURSKY DISTINGUISHED PROFESSOR, WASHINGTON UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
SEEWALDT, VICTORIA	03/20/2016	06/30/2020	RUTH ZIEGLER PROFESSOR AND DEPARTMENT OF POPULATION SCIENCES CHAIR, BECKMAN RESEARCH INSTITUTE, CITY OF HOPE	Special Government Employee (SGE) Member
SHANNON, KEVIN	01/27/2013	06/30/2020	ROMA AND MARVIN AUERBACK DISTINGUISHED PROFESSOR IN PEDIATRIC MOLECULAR ONCOLOGY, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	Special Government Employee (SGE) Member
SIDRANSKY, DAVID	04/29/2019	06/30/2022	DIRECTOR, HEAD AND NECK CANCER RESEARCH AND PROFESSOR OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY, JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE	Special Government Employee (SGE) Member
THOMPSON, IAN	11/26/2017	06/30/2021	PRESIDENT, CHRISTUS SANTA ROSA MEDICAL CENTER HOSPITAL	Special Government Employee (SGE) Member
TUVESON, DAVID	11/26/2017	06/30/2021	ROY J. ZUCKERBERG PROFESSOR, CANCER CENTER DIRECTOR, COLD SPRING HARBOR LABORATORY	Special Government Employee (SGE) Member
VONDERHEIDE, ROBERT	03/17/2019	06/30/2022	PROFESSOR OF MEDICINE, PERELMAN SCHOOL OF MEDICINE AND DIRECTOR, ABRAMSON CANCER CENTER, UNIVERSITY OF PENNSYLVANIA	Special Government Employee (SGE) Member
WHITE, EILEEN	10/08/2014	12/31/2019	CHIEF SCIENCE OFFICER, ASSOCIATE DIRECTOR FOR BASIC RESEARCH, RUTGERS CANCER INSTITUTE OF NEW JERSEY	Special Government Employee (SGE) Member
WHITE, KEVIN	10/27/2014	09/30/2019	JAMES AND KAREN FRANK FAMILY PROFESSOR, UNIVERSITY OF CHICAGO	Special Government Employee (SGE) Member
WILLMAN, CHERYL	10/01/2017	06/30/2021	DIRECTOR AND CEO, UNIVERSITY OF NEW MEXICO COMPREHENSIVE CANCER CENTER	Special Government Employee (SGE) Member

Number of Committee Members Listed: 28

Narrative Description

The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor's (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural

program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA's deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.

What are the most significant program outcomes associated with this committee?

Checked if Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

Outcome Comments

Based on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.

What are the cost savings associated with this committee?

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000

\$5,000,001 - \$10,000,000

Over \$10,000,000

Cost Savings Other



Cost Savings Comments

Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the December 2018 and June 2019 meetings. The Board also met in March 2019.

Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can't be calculated, there are substantive savings.

What is the approximate Number of recommendations produced by this committee for the life of the committee?

324

Number of Recommendations Comments

1. A motion to concur on the Division of Cancer Biology's (DCB's) requests for applications (RFA) entitled "Cellular Cancer Biology Imaging Research Resource Program" was approved with 15 ayes, 1 nay, and no abstentions, with the stipulation that the central theme of the RFA be cancer biology-focused. 2. A motion to concur on the Division of Cancer Treatment and Diagnosis' (DCTD's) RFA entitled "Molecular and Biological Effects of High Linear Energy Transfer Radiation Exposure" was approved unanimously. 3. A motion to concur on the Office of the Director's (OD's) RFA/Cooperative Agreement (Coop. Agr.) entitled "Informatics Technology for Cancer Research" was approved unanimously. 4. A motion to concur on the Division of Cancer Control and Population Science's (DCCPS') RFA entitled "Optimizing Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care" was approved unanimously. 5. A motion to concur on the DCCPS' RFA entitled "Research on Pediatric, Adolescent, and Young Adult Survivorship Through the Childhood Cancer Survivorship, Treatment, Access and Research (STAR) Act" was approved unanimously. 6. A motion to concur on the one-time issuance of OD's RFA entitled "Advancing Cancer Immunotherapy by Mitigating Immune-Related Adverse Events" was approved unanimously. 7. A motion to concur on the one-time issuance of DCCPS' RFA/Coop. Agr. entitled "Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq)" was approved unanimously. 8. A motion to defer on the OD's RFA/Coop. Agr./Request for Proposal (RFP) entitled

“Technologies Development for Use in Next Generation Cancer Models” was approved with 15 ayes, 1 nay, and no abstentions. 9. A motion to approve the 2021 BSA meeting dates was approved unanimously. 10. A motion to concur with establishing a BSA ad hoc Working Group on Prevention was approved unanimously. 11. A motion to approve the BSA exception concurrence for indefinite re-issuance of select Program Announcements with Special Receipt, Referral, and/or Review (PARs), including generic training and diversity funding opportunity announcements (FOAs), and other FOAs was approved unanimously. 12. A motion to concur on the DCCPS’ re-issue RFA/Coop. Agr. (Clinical Trials Not Allowed) entitled “Cancer Intervention and Surveillance Modeling Network (CISNET)” was approved with 22 ayes, zero nays, and 1 abstention. 13. A motion to concur on the OD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “AIDS Malignancy Consortium (AMC)” was approved unanimously. 14. A motion to concur on the DCTD’s re-issue RFP entitled “Cancer Trials Support Unit” was approved unanimously. 15. A motion to concur on the OD’s RFP entitled “Small Business Innovation Research (SBIR) Contract Topics” was approved with 22 ayes, zero nays, and 1 abstention. 16. A motion to concur on the DCCPS’ PAR (Clinical Trials Optional) entitled “Clinical Characterization of Cancer Therapy-Induced Adverse Sequelae and Mechanism-based Interventional Strategies” was approved unanimously. 17. A motion to concur on the OD’s RFA/Administrative Supplement entitled “Activities to Promote Human Immune-Representing Oncology Models Initiative” was approved unanimously. 18. A motion to concur on the OD’s RFA/Coop. Agr. entitled “Next Gen Technology for Next Gen Cancer Models” was approved unanimously. 19. A motion to concur on the OD’s RFA entitled “Mechanisms of Cancer Drug Resistance Competing Revisions” was approved with 19 ayes, zero nays, and 1 abstention. 20. A motion to accept the change in the December 2019 meeting dates of the NCAB and BSA was approved unanimously. 21. A motion to accept the minutes of the 25 March 2019 BSA meeting was approved unanimously. 22. A motion to accept the final report of the BSA ad hoc Working Group on Immunology of Therapies & Vaccines and Research Structure was approved unanimously. 23. A motion to concur on the DCTD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “Pediatric Brain Tumor Consortium” was approved with 14 ayes, zero nays, and 2 abstentions. 24. A motion to concur on the DCTD’s RFP entitled “Clinical Trials Information and Management Contract” was approved with 15 ayes, zero nays, and 1 abstention. 25. A motion to concur on the Division of Cancer Prevention’s (DCP’s) re-issue RFA/Coop. Agr. entitled “Chronic Pancreatitis, Diabetes, and Pancreatic Cancer Consortium” was approved with 7 ayes, 6 nays, and 3 abstentions. 26. A motion to concur on the OD’s RFA/Coop. Agr. entitled “U.S. and Low- and Middle-Income Country (LMIC) HIV Malignancy Research Networks” was approved unanimously. 27. A motion to concur on the DCTD’s re-issue RFA/Coop. Agr. (Limited Competition) entitled “Biospecimen Banks to Support NCI National Clinical Trials Network (NCTN), NCI Community Oncology

Research Program (NCORP), and CTEP-Supported Early Trials/Studies” was approved unanimously. 28. A motion to concur on the DCCPS’ PAR entitled “Co-Infection and Cancer” was approved unanimously. 29. A motion to concur on the re-issue of 17 PARs was approved unanimously.

What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?

90%

% of Recommendations Fully Implemented Comments

The percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>

What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?

10%

% of Recommendations Partially Implemented Comments

The percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at <http://report.nih.gov>.

Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?

Yes No Not Applicable

Agency Feedback Comments

The NCI Director’s Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint

BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.

What other actions has the agency taken as a result of the committee's advice or recommendation?

	Checked if Applies
Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input checked="" type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input type="checkbox"/>

Action Comments

Priorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.

Is the Committee engaged in the review of applications for grants?

No

Grant Review Comments

NA

How is access provided to the information for the Committee's documentation?

	Checked if Applies
Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input checked="" type="checkbox"/>

Access Comments

Information on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at <http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm>. Each NCI committee's charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is

located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: <http://videocast.nih.gov/>.